All In Biotech

Drug Trial Radar · NCT06284122

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 790 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

790

Planned (sponsor's estimate)

Start

Jun 7, 2024

Primary completion

Nov 2028

Study completion Apr 2034

Sponsor

Lead sponsor
The Lymphoma Academic Research OrganisationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Lymphoma Study Association; Swiss Cancer Institute; Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a phase III, randomized, open-label, international, multicenter, interventional trial, designed to compare the efficacy and safety of mosunetuzumab in combination with lenalidomide versus anti-CD20 monoclonal antibody (mAb) plus chemotherapy in patients with previously untreated FLIPI 2-5 follicular lymphoma.

Conditions

  • Follicular Lymphoma

Interventions

  • MosunetuzumabDrug

    5 mg (step-up dosing) Day 1 of C1 45 mg Day 8 and Day 15 of C1, 45 mg Day 1 from C2 to C12, 45 mg Day 1 from C13 to C21

  • LenalidomideDrug

    Lenalidomide starting dose is based on patient's creatinine clearance. Day 1 to Day 21 from C2 to C12

  • RituximabDrug

    when associated to CHOP IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C20

  • ObinutuzumabDrug

    when associated to CHOP 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C18

  • CyclophosphamideDrug

    750 mg/m2 Day 1 from C1 to C6

  • DoxorubicinDrug

    50 mg/m2 Day 1 from C1 to C6

  • VincristinDrug

    1.4 mg/m2 (cap cf. below)$ Day 1 from C1 to C6

  • PrednisoneDrug

    100 mg/day Day 1 to Day 5 from C1 to C6

  • RituximabDrug

    when associated to bendamustin IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C18

  • ObinutuzumabDrug

    when associated to bendamustin 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C20

  • BendamustinDrug

    90 mg/m2 Day 1 and Day 2 from C1 to C6

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: 130 PFS events assessed by an Independent Review Committee (IRC) (4.6 years)
  2. Progression Free Survival (PFS)Time frame: 173 PFS events assessed by IRC (5.8 y)

Locations

111 sites in 7 countries. Site status is shown where the registry gives one.

  • Krankenhaus der Barmherzigen Brüder Graz - Abteilung Für Innere Medizin I

    Graz, Austria

  • Krems University Hospital - Abteilung Für Innere Medizin 2

    Krems, Austria

  • LKH HOCHSTEIERMARK - Department für Hämato-Onkologie

    Leoben, Austria

  • Kepler Universitaetsklinikum - Univ.-Klinik für Hämatologie und Internistische Onkologie

    Linz, Austria

  • Paracelsus Medical University - 3rd Medical Department

    Salzburg, Austria

  • Univ. Klinikum ST.PÖLTEN - Klinische Abteilung Für Innere Medizin 1

    Sankt Pölten, Austria

  • Medical University of Vienna - Department of Hematology and Hemostaseology

    Vienna, Austria

  • Klinikum Wels-Grieskirchen GMBH - IVth Internal Department

    Wels, Austria

  • AZ SINT-JAN BRUGGE - OOSTENDE AV - Service Hématologie

    Bruges, Belgium

  • INSTITUT JULES BORDET - Service Hématologie

    Brussels, Belgium

  • UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Service Hématologie

    Brussels, Belgium

  • GRAND HOPITAL DE CHARLEROI - Service Hématologie

    Charleroi, Belgium

  • UNIVERSITAIR ZIEKENHUIS GENT - Service Hématologie

    Ghent, Belgium

  • HELORA - Hôpital de La Louvière - Site Jolimont - Service Hématologie Clinique

    La Louvière, Belgium

  • CHU DE LIEGE - Service Hématologie

    Liège, Belgium

  • CHU UCL NAMUR - SITE GODINNE - Service Hématologie

    Yvoir, Belgium

  • CH d'AVIGNON - HOPITAL HENRI DUFFAUT - Service d'Onco-Hématologie

    Avignon, France

  • CH DE LA COTE BASQUE - Service Hématologie

    Bayonne, France

  • CHU JEAN MINJOZ - Service Hématologie

    Besançon, France

  • INSTITUT BERGONIE - Service d'Oncologie Médicale

    Bordeaux, France

  • CENTRE HOSPITALIER JEAN ROUGIER - Service d'Oncologie - Hématologie

    Cahors, France

  • CH METROPOLE SAVOIE - SITE CHAMBERY - Service Hématologie

    Chambéry, France

  • CHU ESTAING - Service Thérapie Cellulaire et Hématologie Clinique

    Clermont-Ferrand, France

  • HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes

    Créteil, France

  • CHU DIJON BOURGOGNE - Service Hématologie Clinique

    Dijon, France

  • CHD DE VENDEE - Service Hématologie

    La Roche-sur-Yon, France

  • CHU DE GRENOBLE - Service Hématologie

    La Tronche, France

  • HOPITAL SAINT VINCENT-DE-PAUL - Service Hématologie

    Lille, France

  • CHRU DE LILLE - HOPITAL CLAUDE HURIEZ - Service Hématologie

    Lille, France

  • CHU DE LIMOGES - HOPITAL DUPUYTREN - Service Hématologie Clinique et Thérapie Cellulaire

    Limoges, France

  • INSTITUT PAOLI CALMETTES - Service Hématologie

    Marseille, France

  • CHU DE MONTPELLIER - Département d'Hématologie Clinique

    Montpellier, France

  • GH REGION MULHOUSE ET SUD ALSACE - HOPITAL EMILE MULLER - Service Hématologie

    Mulhouse, France

  • CHU DE NANTES - Service Hématologie

    Nantes, France

  • CENTRE HOSPITALIER DE NIORT - Médecine interne

    Niort, France

  • HOPITAL SAINT-LOUIS - Service Hématologie

    Paris, France

  • CHU DE BORDEAUX - HOPITAL HAUT-LEVEQUE - CENTRE FRANCOIS MAGENDIE - Service d'Hématologie et Thérapie Cellulaire

    Pessac, France

  • CHU LYON-SUD - Hématologie

    Pierre-Bénite, France

  • CHI POISSY SAINT-GERMAIN-EN-LAYE - Service Hématologie

    Poissy, France

  • CHU DE POITIERS - HOPITAL DE LA MILETRIE - Service d'Oncologie Hématologique et Thérapie Cellulaire

    Poitiers, France

Showing 40 of 111 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.